Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Aquestive Therapeutics
(NASDAQ:AQST)
Intraday
$3.10
-0.19
[-5.78%]
After-Hours
$3.10
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$3.10
-0.19
[-5.78%]
At close: May 10
$3.10
0
[0.00%]
After Hours: 6:06PM EDT
Get Report
Watch
Q1 2024 Earnings were released on Tue May 7th, after the market close
The most recent conference call was at 8:00 AM, 3 days ago
Click to view past webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Aquestive Therapeutics Stock (NASDAQ:AQST)
Aquestive Therapeutics Stock (NASDAQ: AQST)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, May 10, 2024
Leerink Partners Initiates Coverage On Aquestive Therapeutics with Outperform Rating, Announces Price Target of $8
Benzinga Newsdesk
-
23 hours ago
Thursday, May 09, 2024
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $9 Price Target
Benzinga Newsdesk
-
2 days ago
Wednesday, May 08, 2024
Aquestive Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.
Benzinga Newsdesk
-
3 days ago
Tuesday, May 07, 2024
Aquestive Therapeutics Continues To Expect FY24 Total Revenue Of $48M-$51M, Est $50.214M
Benzinga Newsdesk
-
3 days ago
Aquestive Therapeutics Q1 2024 GAAP EPS $(0.17) Misses $(0.07) Estimate, Sales $12.053M Miss $12.262M Estimate
Benzinga Newsdesk
-
3 days ago
Tuesday, April 30, 2024
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $9 Price Target
Benzinga Newsdesk
-
Apr 30, 2024, 6:31AM
Monday, April 29, 2024
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Apr 29, 2024, 12:31PM
Aquestive Therapeutics Receives FDA Approval And Market Access For Libervant Buccal Film In Pediatric Patients Ages 2 To 5
Benzinga Newsdesk
-
Apr 29, 2024, 7:04AM
Thursday, April 18, 2024
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
Apr 18, 2024, 1:58PM
Friday, April 12, 2024
Aquestive Therapeutics To Present Crossover Study Data For Libervant Buccal Film At 76th Annual Meeting Of American Academy Of Neurology
Benzinga Newsdesk
-
Apr 12, 2024, 4:02PM
Thursday, April 11, 2024
Piper Sandler Initiates Coverage On Aquestive Therapeutics with Overweight Rating, Announces Price Target of $10
Benzinga Newsdesk
-
Apr 11, 2024, 5:54AM
Friday, April 05, 2024
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $9 Price Target
Benzinga Newsdesk
-
Apr 5, 2024, 6:09AM
Thursday, April 04, 2024
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Apr 4, 2024, 1:21PM
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
Avi Kapoor
-
Apr 4, 2024, 10:44AM
Aquestive Therapeutics shares are trading lower after the company filed for an up to $250 million mixed shelf offering.
Benzinga Newsdesk
-
Apr 4, 2024, 7:36AM
Thursday, March 28, 2024
Raymond James Initiates Coverage On Aquestive Therapeutics with Outperform Rating, Announces Price Target of $7
Benzinga Newsdesk
-
Mar 28, 2024, 7:10AM
Wednesday, March 20, 2024
Dow Surges 350 Points; Fed Holds Rates Steady
Avi Kapoor
-
Mar 20, 2024, 3:22PM
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Mar 20, 2024, 2:03PM
Crude Oil Dips 2%; Signet Jewelers Shares Spike Higher
Avi Kapoor
-
Mar 20, 2024, 12:47PM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Mar 20, 2024, 9:05AM
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Mar 20, 2024, 8:20AM
Aquestive Therapeutics shares are trading lower after the company announced the pricing of a $75 million underwritten public offering of 16,666,667 shares at $4.50 per share.
Benzinga Newsdesk
-
Mar 20, 2024, 7:31AM
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Avi Kapoor
-
Mar 20, 2024, 5:32AM
Reported Earlier, Aquestive Therapeutics Prices $75M Underwritten Public Offering Of 16,666,667 Common Shares At $4.50/Share
Benzinga Newsdesk
-
Mar 20, 2024, 2:09AM
Tuesday, March 19, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Mar 19, 2024, 5:34PM
Aquestive Therapeutics shares are trading lower after the company announced a proposed public offering.
Benzinga Newsdesk
-
Mar 19, 2024, 4:04PM
Aquestive Therapeutics Announces Proposed Public Offering Of Common Stock; Size Not Disclosed
Benzinga Newsdesk
-
Mar 19, 2024, 4:02PM
Monday, March 18, 2024
HC Wainwright & Co. Maintains Buy on Aquestive Therapeutics, Raises Price Target to $9
Benzinga Newsdesk
-
Mar 18, 2024, 6:48AM
Friday, March 15, 2024
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Mar 15, 2024, 2:31PM
Aquestive Therapeutics shares are trading higher after the company announced Anaphylm met all predefined primary and secondary pharmacokinetic endpoints.
Benzinga Newsdesk
-
Mar 15, 2024, 12:17PM
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Mar 15, 2024, 8:13AM
JMP Securities Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $10
Benzinga Newsdesk
-
Mar 15, 2024, 6:59AM
Thursday, March 14, 2024
Aquestive Therapeutics Says Anaphylm Meets All Predefined Primary And Secondary Pharmacokinetic Endpoints; Reaffirms Goal Of Filing NDA Before The End Of 2024
Benzinga Newsdesk
-
Mar 14, 2024, 5:26PM
Monday, March 11, 2024
HC Wainwright & Co. Maintains Buy on Aquestive Therapeutics, Raises Price Target to $7
Benzinga Newsdesk
-
Mar 11, 2024, 7:34AM
Friday, March 08, 2024
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Mar 8, 2024, 1:47PM
Thursday, March 07, 2024
Aquestive Therapeutics shares are trading higher after analysts at Wedbush and Lake Street raised their price targets on the stock.
Benzinga Newsdesk
-
Mar 7, 2024, 3:33PM
Wedbush Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $9
Benzinga Newsdesk
-
Mar 7, 2024, 12:30PM
Lake Street Maintains Buy on Aquestive Therapeutics, Raises Price Target to $8
Benzinga Newsdesk
-
Mar 7, 2024, 12:01PM
Tuesday, March 05, 2024
Aquestive Therapeutics Q4 2023 Adj EPS $(0.100) Misses $(0.080) Estimate, Sales $13.206M Beat $11.631M Estimate
Benzinga Newsdesk
-
Mar 5, 2024, 5:19PM
Earnings Scheduled For March 5, 2024
Benzinga Insights
-
Mar 5, 2024, 5:00AM
Monday, March 04, 2024
A Preview Of Aquestive Therapeutics's Earnings
Benzinga Insights
-
Mar 4, 2024, 12:02PM
Thursday, February 15, 2024
Aquestive Therapeutics To Present Anaphylm Sublingual Film Pharmacokinetic And Pharmacodynamic Data At 2024 AAAAI Annual Meeting
Benzinga Newsdesk
-
Feb 15, 2024, 8:08AM
Tuesday, December 05, 2023
Aquestive Therapeutics Has Dosed First Patient In Phase 3 Pivotal Pharmacokinetic Study Of Anaphylm
Benzinga Newsdesk
-
Dec 5, 2023, 8:03AM
Friday, November 10, 2023
Aquestive Therapeutics To Present Data From Pharmacokinetic And Pharmacodynamic Studies For Anaphylm At American College Of Allergy Asthma And Immunology Annual Meeting
Benzinga Newsdesk
-
Nov 10, 2023, 8:07AM
Wednesday, November 08, 2023
Where Aquestive Therapeutics Stands With Analysts
Benzinga Insights
-
Nov 8, 2023, 2:00PM
HC Wainwright & Co. Maintains Buy on Aquestive Therapeutics, Raises Price Target to $6
Benzinga Newsdesk
-
Nov 8, 2023, 8:19AM
Monday, November 06, 2023
Aquestive Therapeutics Q3 2023 EPS $(0.03) Beats $(0.11) Estimate, Sales $13.00M Beat $11.51M Estimate
Benzinga Newsdesk
-
Nov 6, 2023, 5:06PM
Earnings Scheduled For November 6, 2023
Benzinga Insights
-
Nov 6, 2023, 8:24AM
Friday, November 03, 2023
Preview: Aquestive Therapeutics's Earnings
Benzinga Insights
-
Nov 3, 2023, 4:01PM
Tuesday, October 10, 2023
Wedbush Reiterates Outperform on Aquestive Therapeutics, Maintains $4 Price Target
Benzinga Newsdesk
-
Oct 10, 2023, 8:59AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch